Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer who have disease progression after therapy with multiple HER2-targeted agents have limited treatment options. Tucatinib is an investigational, oral, highly selective inhibitor of the HER2 tyrosine kinase. METHODS: We randomly assigned patients with HER2-positive metastatic breast cancer previously treated with trastuzumab, pertuzumab, and trastuzumab emtansine, who had or did not have brain metastases, to receive either tucatinib or placebo, in combination with trastuzumab and capecitabine. The primary end point was progression-free survival among the first 480 patients who underwent randomization. Secondary end points, assessed in the total population (612 patients), included overall survival, progression-free survival among patients with brain metastases, confirmed objective response rate, and safety. RESULTS: Progression-free survival at 1 year was 33.1% in the tucatinib-combination group and 12.3% in the placebo-combination group (hazard ratio for disease progression or death, 0.54; 95% confidence interval [CI], 0.42 to 0.71; P<0.001), and the median duration of progression-free survival was 7.8 months and 5.6 months, respectively. Overall survival at 2 years was 44.9% in the tucatinib-combination group and 26.6% in the placebo-combination group (hazard ratio for death, 0.66; 95% CI, 0.50 to 0.88; P = 0.005), and the median overall survival was 21.9 months and 17.4 months, respectively. Among the patients with brain metastases, progression-free survival at 1 year was 24.9% in the tucatinib-combination group and 0% in the placebo-combination group (hazard ratio, 0.48; 95% CI, 0.34 to 0.69; P<0.001), and the median progression-free survival was 7.6 months and 5.4 months, respectively. Common adverse events in the tucatinib group included diarrhea, palmar-plantar erythrodysesthesia syndrome, nausea, fatigue, and vomiting. Diarrhea and elevated aminotransferase levels of grade 3 or higher were more common in the tucatinib-combination group than in the placebo-combination group. CONCLUSIONS: In heavily pretreated patients with HER2-positive metastatic breast cancer, including those with brain metastases, adding tucatinib to trastuzumab and capecitabine resulted in better progression-free survival and overall survival outcomes than adding placebo; the risks of diarrhea and elevated aminotransferase levels were higher with tucatinib. (Funded by Seattle Genetics; HER2CLIMB ClinicalTrials.gov number, NCT02614794.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This was achieved at the expense of increased toxicity, mostly diarrhoea and elevated aminotransferase levels of grade ≥3, but did not lead to frequent treatment discontinuation.”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [62]
In the citing paper
“Tucatinib, a highly selective inhibitor of the HER2 tyrosine kinase, used in combination with capecitabine and trastuzumab in a population of ABC patients pretreated with trastuzumab, pertuzumab and trastuzumab emtansine (T-DM1), demonstrated improvement of PFS (median 7.8 months versus 5.6 months, HR 0.54; 95% CI 0.42-0.71, P < 0.001) and OS (median 21.9 months versus 17.4 months, HR 0.66; 95% CI”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [62]
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
The National Comprehensive Cancer Network (NCCN).
Wood, E. H. (2004) · Journal of the Medical Library Association JMLA · Cited by 2,845
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
Baselga, J., Cortés, J., Kim, S.-B., Im, S.-A., Hegg, R., Im, Y.-H., Roman, L., Pedrini, J. L., Pienkowski, T., Knott, A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113216 · Cited by 2,532
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
Cardoso, F., Costa, A., Senkus, E., Aapro, M., André, F., Barrios, C. H., Bergh, J., Bhattacharyya, G., Biganzoli, L., Cardoso, M. J., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdw544 · Cited by 2,033
Self-citationBendell, J. C., Domchek, S. M., Burstein, H. J., Harris, L., Younger, J., Kuter, I., Bunnell, C., Rue, M., Gelman, R., & Winer, E. (2003) · Cancer · doi:10.1002/cncr.11436 · Cited by 1,320
Self-citation4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)
Cardoso, F., Senkus, E., Costa, A., Papadopoulos, E., Aapro, M., André, F., Harbeck, N., Aguilar Lopez, B., Barrios, C. H., Bergh, J., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy192 · Cited by 1,171
Self-citationSwain, S. M., Kim, S.-B., Cortés, J., Ro, J., Semiglazov, V., Campone, M., Ciruelos, E., Ferrero, J.-M., Schneeweiss, A., Knott, A., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70130-x · Cited by 1,006
Bachelot, T., Romieu, G., Campone, M., Diéras, V., Cropet, C., Dalenc, F., Jimenez, M., Le Rhun, E., Pierga, J.-Y., Gonçalves, A., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70432-1 · Cited by 737
Self-citationLin, N. U., Diéras, V., Paul, D., Lossignol, D., Christodoulou, C., Stemmler, H.-J., Roché, H., Liu, M. C., Greil, R., Ciruelos, E., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1080 · Cited by 658
Self-citationOwens, M. A., Horten, B. C., & Da Silva, M. M. (2004) · Clinical Breast Cancer · doi:10.3816/cbc.2004.n.011 · Cited by 657
Research works printed but not linked: 1
- Pheneger T, Bouhana K, Anderson D, et al. In vitro and in vivo activity of ARRY-380: a potent, small molecule inhibitor of ErbB2. Cancer Res 2009;69:1795-1795. abstract.
Cited by
Items 601–700 of 1,000
Chan, C., Prozzo, V., Aghevlian, S., & Reilly, R. M. (2022) · EJNMMI Radiopharmacy and Chemistry · doi:10.1186/s41181-022-00186-9 · Cited by 9
“In addition, several new targeted agents for treating HER2-positive BC have recently been introduced including the TKI tucatinib (Tukysa; Cascadian Therapeutics) (Murthy et al.”
BackgroundZhu, X., Ding, Y., Wang, Q., Yang, G., Zhou, L., & Wang, Q. (2023) · Investigational New Drugs · doi:10.1007/s10637-023-01338-7 · Cited by 9
Guidi, L., Valenza, C., Trapani, D., & Curigliano, G. (2023) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2023.2277915 · Cited by 9
“In some instances, novel agents like the brain-penetrant TKI Tucatinib, have ‘resolved’ historical challenges, for example through its activity in brain-progressing, pre-treated BC, as shown in the pivotal phase II HER2CLIMB study [8].”
BackgroundSelf-citationEvolution of the Management of Brain Metastases: A Bibliometric Analysis
Burney, I. A., Hamad, A. A., Hashmi, S. F., Ahmad, N., & Pervez, N. (2023) · Cancers · doi:10.3390/cancers15235570 · Cited by 9
“Eventually, to ensure related articles were included, all cited articles were compared with the reference list in the following studies: Mok, Wu [24], Murthy, Loi [25], Brown, Jaeckle [26], and Chang, Shi [27].”
BackgroundResultMichaeli, J. C., Michaeli, T., Trapani, D., Albers, S., Dannehl, D., Würstlein, R., & Michaeli, D. T. (2024) · Breast Cancer · doi:10.1007/s12282-024-01634-x · Cited by 9
“…trastuzumab and capecitabine for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting” based on the HER2CLIMB trial [23].”
Yuan, Y., Lee, J. S., Yost, S. E., Stiller, T., Blanchard, M. S., Padam, S., Katheria, V., Kim, H., Sun, C., Tang, A., et al. (2021) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2021.02.020 · Cited by 10
Nakayama, T., Yoshinami, T., Yasojima, H., Kittaka, N., Takahashi, M., Ohtani, S., Kim, S. J., Kurakami, H., Yamamoto, N., Yamada, T., et al. (2021) · BMC Cancer · doi:10.1186/s12885-021-08504-1 · Cited by 9
“The HER2CLIMB study recently reported that the addition of tucatinib to trastuzumab and capecitabine improved both PFS and OS in heavily pretreated patients with HER2-positive breast cancer, including those with CNS metastases [26].”
BackgroundWang, T., Zhang, Y., He, Y., Liu, Y., & Qi, P. (2021) · BioMed Research International · doi:10.1155/2021/5575286 · Cited by 10
McAndrew, N. P. (2021) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/gco.0000000000000762 · Cited by 9
“Toxicity with tucatinib, capecitabine, and trastuzumab is comparable to the previously reported toxicity profile of capecitabine and TKIs, which includes diarrhea, palmar-plantar erythema, nausea/vomiting, and fatigue [25].”
BackgroundResultClinical Potential of miR-451 and miR-506 as a Prognostic Biomarker in Patients with Breast Cancer
Du, Y., Miao, Z., Qiu, L., Lv, Y., Wang, K., & Guo, L. (2022) · Journal of Healthcare Engineering · doi:10.1155/2022/9578788 · Cited by 9
RetractedInactivating Amplified HER2: Challenges, Dilemmas, and Future Directions
Moasser, M. M. (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-1121 · Cited by 9
Koide, Y., Nagai, N., Miyauchi, R., Kitagawa, T., Aoyama, T., Shimizu, H., Tachibana, H., & Kodaira, T. (2022) · Journal of Neuro-Oncology · doi:10.1007/s11060-022-04132-2 · Cited by 9
Jacob, S. L., Johnson, M., Roque, B., Quintal, L., Rugo, H. S., Melisko, M., & Chien, A. J. (2023) · Clinical Breast Cancer · doi:10.1016/j.clbc.2023.06.014 · Cited by 9
Appraisal of Systemic Treatment Strategies in Early HER2-Positive Breast Cancer—A Literature Review
Mata, D. G. D. M. M., Chehade, R., Hannouf, M. B., Raphael, J., Blanchette, P., Al-Humiqani, A., & Ray, M. (2023) · Cancers · doi:10.3390/cancers15174336 · Cited by 10
“The HER2CLIMB trial tested the addition of oral tucatinib with capecitabine and trastuzumab in metastatic HER2+ BC and showed an increased OS and PFS in patients previously treated with H+P and T-DM1 [7,132].”
MethodAddressing Residual Disease in HER2-Positive and Triple-Negative Breast Cancer: What Is Next?
Schlam, I. M., Dower, J., & Lynce, F. C. (2024) · Current Oncology Reports · doi:10.1007/s11912-024-01501-0 · Cited by 9
“HER2-directed TKIs have shown to have CNS activity and combining an ADC with a TKI in the post-neo-adjuvant setting is an attractive alternative [41].”
Edirin, O. J., & Carrick, J. D. (2024) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.4c00627 · Cited by 9
HER2-targeted agents overcome resistance
Sidaway, P. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0325-y · Cited by 9
The changing treatment of metastatic her2‑positive breast cancer (Review)
Mitsogianni, M., Trontzas, I. P., Gomatou, G., Ioannou, S., Syrigos, N. K., & Kotteas, E. A. (2021) · Oncology Letters · doi:10.3892/ol.2021.12548 · Cited by 12
Díaz-Gil, L., Brasó‐Maristany, F., Locatelli, C., Centa, A., Győrffy, B., Ocaña, A., Prat, A., & Pandiella, A. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02098-z · Cited by 10
Neu Perspectives, Therapies, and Challenges for Metastatic HER2-Positive Breast Cancer
Salkeni, M. A., Rizvi, W., Hein, K. Z., & Higa, G. M. (2021) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s288344 · Cited by 10
“Lapatinib is a reversible, bi-specific inhibitor of EGFR and HER2.”
BackgroundMethodInfluentialChew, S. M., Carroll, H. K., Darwish, W., Boychak, O. V., Higgins, M. J., McCaffrey, J., & Kelly, C. M. (2021) · Cancer Management and Research · doi:10.2147/cmar.s330829 · Cited by 9
Chi, Y., Shang, M., Xu, L., Gong, H., Tao, R., Song, L., Zhang, B., Yin, S., Cong, B., & Li, H. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.811919 · Cited by 10
Multifocal and pathologically-confirmed brain metastasis complete response to trastuzumab deruxtecan
Moss, N. S., Tosi, U., Santomasso, B., Beal, K. P., & Modi, S. (2022) · CNS Oncology · doi:10.2217/cns-2022-0010 · Cited by 9
Trastuzumab therapy duration in HER2-positive de novo metastatic breast cancer: 1999–2018
Kaplan, H. G., Malmgren, J. A., Guo, B., & Atwood, M. K. (2022) · Breast Cancer Research and Treatment · doi:10.1007/s10549-022-06678-1 · Cited by 9
“Going forward the development of multiomic analysis of plasma as well as new, effective HER2-specific treatment options may also influence treatment decisions [30, 31, 40, 41].”
BackgroundLiu, J., Sun, X., Du, Q., Yao, J., Dai, M., Cheng, Q., Han, X., Li, Y., Liu, X., Zhang, M., et al. (2022) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s385341 · Cited by 11
“Due to the different HER2-targeting domains and synergistic drug interactions, dual anti-HER2 therapy with trastuzumab and TKIs has been proven to provide synergistic antitumor activity and a significant outcome benefit.(9,10) Li et al reported in a real-world study that the mPFS of pyrotinib combined with trastuzumab…”
BackgroundAntibody-Drug Conjugates Used in Breast Cancers
Abbas, A., Ibrahim, M. F., & Saifo, M. (2021) · Journal of Oncology · doi:10.1155/2021/9927433 · Cited by 9
“However, resistance to trastuzumab has been reported [8, 9], in addition to several severe adverse effects such as cardiac toxicity [10].”
BackgroundA view on the landscape of breast cancer brain metastases
Malani, R. (2020) · CNS Oncology · doi:10.2217/cns-2020-0013 · Cited by 9
“A Phase Ib trial of tucatinib with trastuzumab and capecitabine showed that in 12 patients with BCBM at baseline, 42% achieved an objective response in the brain [11,35,37].”
BackgroundPTPRO inhibits LPS-induced apoptosis in alveolar epithelial cells
Li, X., Xiong, Q., Yang, Q., Shi, J., Han, Y., Dong, Y., Qian, J., Qian, Z., Wang, H., Wang, T., et al. (2024) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2024.150083 · Cited by 8
Astore, M., Fabbri, L., Monte, A., Deiana, C., Rizzo, A., Tavolari, S., Deserti, M., Brandi, G., Palloni, A., & Frega, G. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262411961 · Cited by 9
Jerzak, K. J., Razis, E. D., Agostinetto, E., Brastianos, P. K., Gatti-Mays, M. E., Ahluwalia, M. S., Anders, C., Bartsch, R. A., Cardoso, F., de Vries, E. G. E., et al. (2025) · npj Breast Cancer · doi:10.1038/s41523-025-00856-2 · Cited by 11
“%) had stable/previously treated CNS metastases 42 .”
Self-citationKim, M., Shim, H. S., Kim, S., Lee, I. H., Kim, J., Yoon, S., Kim, H., Park, I., Jeong, J. H., Yoo, C., et al. (2023) · Cancer Research and Treatment · doi:10.4143/crt.2023.1043 · Cited by 8
Prezelski, K., Hsu, D. G., del Balzo, L., Heller, E., Ma, J., Pike, L., Ballangrud, Å., & Aristophanous, M. (2024) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdae015 · Cited by 8
“8–12 The combination of prolonged survival with a local management approach for BMs means that patients may receive multiple courses of SRS after locoregional failure.”
BackgroundUpdate Breast Cancer 2024 Part 1 – Expert Opinion on Advanced Breast Cancer
Würstlein, R., Kolberg, H., Hartkopf, A. D., Fehm, T. N., Welslau, M., Schütz, F., Fasching, P. A., Janni, W. J., Witzel, I., Thomssen, C., et al. (2024) · Geburtshilfe und Frauenheilkunde · doi:10.1055/a-2300-5326 · Cited by 8
Self-citationHartkopf, A. D., Walter, C. B., Kolberg, H., Hadji, P., Tesch, H., Fasching, P. A., Ettl, J., Lüftner, D., Wallwiener, M., Müller, V., et al. (2024) · Geburtshilfe und Frauenheilkunde · doi:10.1055/a-2286-5372 · Cited by 8
Self-citationMichelon, I. F., Castro, C., Madeira, T., Dacoregio, M. I., Stecca, C., Soares, L. R., Saeed, A., Vilbert, M., & Cavalcante, L. L. (2025) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2025.102882 · Cited by 10
Ferraro, E., Reiner, A. S., Nassif, R. B., Tosi, U., Brown, S., Zeller, S., Dang, C. T., Seidman, A. D., & Moss, N. S. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.57483 · Cited by 8
Targeted Therapies for Breast Cancer Brain Metastases
Daylan, A. E. C., & Leone, J. P. (2020) · Clinical Breast Cancer · doi:10.1016/j.clbc.2020.11.014 · Cited by 8
Haque, W. M., Verma, V., Adeberg, S., Rustomily, R., Lo, S. S.-M., Butler, E. B., & Teh, B. S. (2021) · Reports of Practical Oncology & Radiotherapy · doi:10.5603/rpor.a2021.0045 · Cited by 8
“Moreover, a recent study demonstrated that tucatinib, an oral TKI selective for HER2, can improve OS in patients with HER2+ breast cancer and BM, though future studies will be required to determine how best to incorporate intracranial RT and tucatinib to maximize OS while minimizing neurocognitive toxicity in this pat…”
BackgroundJoe, N., Hodgdon, C., Kraemer, L., Redmond, K. J., Stearns, V., & Gilkes, D. M. (2021) · npj Breast Cancer · doi:10.1038/s41523-021-00326-5 · Cited by 10
Landscape of Epidermal Growth Factor Receptor Heterodimers in Brain Metastases
Lim, M., Nguyen, T. H., Niland, C., Reid, L., Jat, P., Saunus, J. M., & Lakhani, S. R. (2022) · Cancers · doi:10.3390/cancers14030533 · Cited by 8
Bhogal, T., Cameron, D., & Palmieri, C. (2022) · The Breast · doi:10.1016/j.breast.2022.03.013 · Cited by 8
“Only 4 of 16 (25%) non-CNS prevention trials had protocol defined CNS specific endpoints [11,20,21,25].”
BackgroundMethodInfluentialSelf-citationBick, G., Zhang, J., Lowe, E. E., & Zhang, X. (2022) · Cancer Drug Resistance · doi:10.20517/cdr.2022.33 · Cited by 8
Synthesis and in vivo evaluation of [11C]tucatinib for HER2-targeted PET imaging
Müller, M., Shalgunov, V., Hvass, L., Jørgensen, J. T., Kramer, V., Staudt, M., Battisti, U. M., Kjær, A., & Herth, M. M. (2022) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2022.129088 · Cited by 8
Kuntz, L., Fèvre, C. L., Jarnet, D., Keller, A., Meyer, P., Thiéry, A., Cébula, H., Noël, G., & Antoni, D. (2023) · Radiation Oncology · doi:10.1186/s13014-023-02200-z · Cited by 8
Current Treatment Approaches to Breast Cancer
Mir, M. A., & Mir, A. Y. (2023) · Springer eBooks · doi:10.1007/978-981-19-8911-7_2 · Cited by 10
Faleh, S., Prakash, I., Eisenberg, E., Basik, M., Boileau, J. F., Tejera, D., Panet, F., Buhlaiga, N., Meterissian, S. H., & Wong, S. M. (2023) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2023.03.226 · Cited by 8
Available Systemic Treatments and Emerging Therapies for Breast Cancer Brain Metastases
Rader, R. K., Anders, C. K., Lin, N., & Sammons, S. L. (2023) · Current Treatment Options in Oncology · doi:10.1007/s11864-023-01086-z · Cited by 8
“Freedman R.A., Ren S., Tayob N., Gelman R.S., Smith K.L., Davis R., et al. Neratinib and ado-trastuzumab emtansine (T-DM1) for HER2+ breast cancer brain metastases (BCBM): Translational Breast Cancer Research Consortium (TBCRC) Trial 022.”
MethodInfluentialSelf-citationZambelli, A., Cazzaniga, M. E., Verde, N. M. L., Munzone, E., Antonazzo, I. C., Mantovani, L. G., Cosimo, S. D., Mancuso, A. M., Generali, D., & Cortesi, P. A. (2023) · The Breast · doi:10.1016/j.breast.2023.08.005 · Cited by 8
“control arm of the DESTINY BREAST 02 and/or HER2CLIMB clinical trials) [24,25].”
MethodStereotactic Radiosurgery for Women Older than 65 with Breast Cancer Brain Metastases
Upadhyay, R., Klamer, B. G., Perlow, H. K., White, J. R., Bazan, J. G., Jhawar, S. R., Blakaj, D. M., Grecula, J. C., Arnett, A. L. H., Mestres-Villanueva, M. A., et al. (2023) · Cancers · doi:10.3390/cancers16010137 · Cited by 8
“This is likely due in part to the recent development of multiple HER2 directed systemic therapies including Trastuzumab, TDM-1, Tucatinib, and Enhertu [44,45].”
Blondeaux, E., Ferreira, A. R., Poggio, F. B., Puglisi, F., Bighin, C., Sottotetti, F., Montemurro, F., Poletto, E., Lai, A., Sini, V., et al. (2020) · ESMO Open · doi:10.1136/esmoopen-2020-000719 · Cited by 8
Neratinib plus capecitabine for the treatment of advanced HER2-positive breast cancer
Oliveira, M., Garrigós, L., Assaf, J. D., Escrivá-de-Romaní, S., & Saura, C. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2020.1807947 · Cited by 8
“The results from HER2-Climb with the triplet combination of tuca-tinib, trastuzumab, and capecitabine led to the FDA approval of this regimen in patients with HER2-positive MBC who have received at least one line of anti-HER2 therapy in the metastatic setting (see Section 2.2) [19].”
InfluentialSelf-citationKruse, M. L., Kang, I. M., Bagegni, N. A., Howell, W., Moore, H. C. F., Bedell, C., & Stokoe, C. T. (2021) · Oncology and Therapy · doi:10.1007/s40487-021-00178-w · Cited by 8
Sanglier, T., Shim, J., Lamarre, N., Peña-Murillo, C., Antao, V., & Montemurro, F. (2023) · The Breast · doi:10.1016/j.breast.2023.01.007 · Cited by 8
McMahon, J. T., Faraj, R. R., & Adamson, D. C. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1836154 · Cited by 8
Immunotherapy as a partner for HER2-directed therapies
Clifton, G. T., & Peoples, A. G. E. (2021) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2021.1894932 · Cited by 10
Sexual abuse and obesity: implications for the treatment of obesity.
King, T. K. (1997) · PubMed · Cited by 8
Recent Advances in the Development and Clinical Use of HER2 Inhibitors in Non-Small Cell Lung Cancer
Ekyalongo, R., Yamaoka, T., & Tsurutani, J. (2025) · Biomolecules · doi:10.3390/biom15101443 · Cited by 7
“Dual HER2-targeted regimens, such as tucatinib in combination with trastuzumab and capecitabine, have demonstrated efficacy in HER2-positive breast cancer [56].”
Characterization of patients with brain metastases referred to palliative care
Harrison, R. A., Tang, M. J., Shih, K. K., Khan, M. R., Pham, L., de Moraes, A. R., O'Brien, B. J., Bassett, R. L., & Bruera, E. D. (2024) · BMC Palliative Care · doi:10.1186/s12904-023-01320-3 · Cited by 8
“While traditionally excluded from clinical trials, the approach to these patients is changing, with new clinical and academic dedication to developing impactful therapies in this population [3, 4].”
BackgroundPerformance of a HER2 testing algorithm tailored for urothelial bladder cancer: A Bi-centre study
Huang, A., Zhao, Y., Guan, F., Zhang, H., Luo, B., Xie, T., Chen, S.-J., Chen, X., Ai, S., Ju, X., et al. (2024) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2024.10.007 · Cited by 7
“Anti-HER2 therapy, which includes monoclonal antibodies such as trastuzumab and pertu-zumab, as well as tyrosine kinase inhibitors like lapatinib and tucatinib, has been successfully applied to patients with HER2-positive breast cancer [17,18].”
BackgroundTang, X., Wang, C., Li, Y., Tang, J. P., Zhang, G., & Chen, L. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1538881 · Cited by 8
“Despite these advancements, TKI therapies are associated with signi fi cant side effects that can reduce patients ’ quality of life and increase the likelihood of treatment interruptions, potentially resulting in higher mortality rates (Saura et al., 2020; Murthy et al., 2020).”
Bruzzone, F., Barigazzi, C., Muzio, A. D., Tallarico, I., Dipasquale, A., Losurdo, A., Persico, P., Navarria, P., Pessina, F., Santoro, A., et al. (2025) · Cancers · doi:10.3390/cancers17091591 · Cited by 10
“Whether pretreated or not, the outstanding efficacy of T-DXd in stable HER-2 + BMs suggests it may be preferred over other active regimens such as T-DM1 or the Trastuzumab–Tucatinib–Capecitabine combination [74,78,116].”
Update Breast Cancer 2020 Part 5 – Moving Therapies From Advanced to Early Breast Cancer Patients
Lux, M. P., Schneeweiß, A., Hartkopf, A. D., Müller, V., Janni, W., Belleville, E., Stickeler, E., Thill, M., Fasching, P. A., Kolberg, H., et al. (2021) · Geburtshilfe und Frauenheilkunde · doi:10.1055/a-1397-7170 · Cited by 7
Self-citationMoy, B., Oliveira, M., Saura, C., Gradishar, W. J., Kim, S., Brufsky, A., Hurvitz, S. A., Ryvo, L., Fagnani, D., Kalmadi, S. R., et al. (2021) · Breast Cancer Research and Treatment · doi:10.1007/s10549-021-06217-4 · Cited by 7
Self-citationConcurrent Radiation and Modern Systemic Therapies for Breast Cancer: An Ever-Expanding Frontier
Witt, J. S., Wisinski, K. B., & Anderson, B. M. (2021) · Clinical Breast Cancer · doi:10.1016/j.clbc.2020.11.019 · Cited by 7
A nomogram for predicting brain metastasis in patients with de novo stage IV breast cancer
Sun, M.-S., Liu, Y., Ye, J., Liu, Q., Cheng, Y., Xin, L., & Xu, L. (2021) · Annals of Translational Medicine · doi:10.21037/atm-21-1808 · Cited by 9
“4325 (100) 3589 (83) 2667 (62) 1850 (43) 1194 (28) 731 (17) 410 (9) 191 (4) 60 (1) 2829 (100) 2044 (72) 1336 (47) 856 (30) 544 (19) 315 (11) 179 (6) 84 (3) 22 (1) Above Mean Below Mean Number at risk: n (%) 0 10 20 30 40 50 60 70 80 O ve ra ll su rv iv al (1 00 % )”
BackgroundAdverse events of targeted therapies approved for women's cancers
Saint‐Ghislain, M., Levenbruck, C., & Bellesœur, A. (2021) · International Journal of Women’s Dermatology · doi:10.1016/j.ijwd.2021.10.006 · Cited by 7
Guan, X., Ma, F., & Xu, B. (2022) · Cancer Innovation · doi:10.1002/cai2.21 · Cited by 7
“…complete response rate was achieved by the combination of lapatinib plus trastuzumab for the neoadjuvant setting in the NeoALTTO study [7], and a significant survival benefit was gained by the combination of tucatinib plus trastuzumab for previously treated patients in the HER2CLIMB study [8].”
BackgroundZhang, X., Li, Z., Han, L., Lv, Z., Teng, Y., Cui, X., Zhou, C., Wu, H., Fang, W., Xu, L., et al. (2022) · OncoTargets and Therapy · doi:10.2147/ott.s379591 · Cited by 7
Recent trends of characteristics and treatments in adults with newly diagnosed brain metastases
Koide, Y., Nagai, N., Miyauchi, R., Kitagawa, T., Aoyama, T., Shimizu, H., Hashimoto, S., Tachibana, H., & Kodaira, T. (2023) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyad026 · Cited by 8
Vyas, B., Kumar, S., Bhowmik, R., & Akhter, M. (2023) · Scientific Reports · doi:10.1038/s41598-023-40684-7 · Cited by 7
“Interaction analyses of the docked poses of tucatinib 38 showed that the drug is a persuasive inhibitor of 3M7P, 3G73 and 4Y29.”
BackgroundWang, J., Yu, Y., Lin, Q., Zhang, J., & Song, C. (2024) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-05530-3 · Cited by 7
“In the brain metastasis subgroup of the HER2CLIMB study, the 1-year PFS was much higher in the tucatinib group than in the control group (24.9% vs 0%, HazR 0.48; 95%CI 0.34–0.69; p < 0.001)(Murthy et al. 2020).”
InfluentialO’Neill, C. E., Sun, K., Sundararaman, S., Chang, J. C., & Glynn, S. A. (2024) · Frontiers in Physiology · doi:10.3389/fphys.2024.1358850 · Cited by 7
“Most recently, a newer-generation TKI tucatinib, in combination with capecitabine and trastuzumab, for the fi rst time, demonstrated clinically meaningful bene fi ts in patients with HER2-positive active brain metastases (Murthy et al., 2020).”
BackgroundScandurra, G., Lombardo, V., Scibilia, G., Sambataro, D., Gebbia, V., Scollo, P., Pecorino, B., & Valerio, M. R. (2024) · Cancers · doi:10.3390/cancers16132466 · Cited by 7
“In this subgroup, the addition of tucatinib led to a remarkable improvement in PFS compared to placebo, with a PFS rate of 24.9% versus 0% at 1 year [91].”
BackgroundInfluentialZhang, X., Leng, J., Zhou, Y., Mao, F., Lin, Y., Shen, S., & Sun, Q. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.731210 · Cited by 8
Diaby, V., Almutairi, R., Babcock, A., Moussa, R. K., & Ali, A. A. (2020) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1080/14737167.2021.1848553 · Cited by 8
“The current review also uncovers the limited evidence to support decisions about the value for HR-positive/HER2-positive mBC and biosimilars for targeted-directed therapies, including neratinib [41] trastuzumab deruxtecan [42] and tucatinib [43] creating at the same time an opportunity for further research.”
BackgroundUpdate Breast Cancer 2021 Part 2 – Advanced Stages, Long-Term Consequences and Biomarkers
Ditsch, N., Stickeler, E., Behrens, A. S., Belleville, E., Fasching, P. A., Fehm, T. N., Hartkopf, A. D., Jackisch, C., Janni, W., Kolberg‐Liedtke, C., et al. (2021) · Geburtshilfe und Frauenheilkunde · doi:10.1055/a-1464-1221 · Cited by 8
“48% of the patients had brain metastases [39].”
Self-citationFeng, C., Virparia, R., & Mui, E. T.-K. (2021) · Therapeutic Innovation & Regulatory Science · doi:10.1007/s43441-021-00296-7 · Cited by 7
Ge, J. Y., & Overmoyer, B. A. (2021) · Case Reports in Oncology · doi:10.1159/000516760 · Cited by 7
Landmark trials in the medical oncology management of metastatic breast cancer
Lu, P., Santa-Maria, C. A., Ballinger, T. J., & Sheng, J. Y.-S. (2021) · Seminars in Oncology · doi:10.1053/j.seminoncol.2021.06.003 · Cited by 7
Cardiovascular Diseases Following Breast Cancer
Méry, B., Rowinski, E., Rivier, C., Bouleftour, W., Sotton, S., Tinquaut, F., Bertoletti, L., Trédan, O., & Magné, N. (2022) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000904 · Cited by 7
Radiotherapy for Leptomeningeal Carcinomatosis in Breast Cancer Patients: A Narrative Review
Pawłowska, E., Romanowska, A., & Jassem, J. (2022) · Cancers · doi:10.3390/cancers14163899 · Cited by 9
“Low molecular weight HER2-tyrosine kinase inhibitors, such as lapatinib, neratinib, and tucatinib, have been shown to be effective in BC patients with BM, but there are scarce data on their activity in LC [63,64].”
BackgroundTreatment of Brain Metastases: The Synergy of Radiotherapy and Immune Checkpoint Inhibitors
Matsui, J. K., Perlow, H. K., Raj, R. K., Nalin, A. P., Lehrer, E. J., Kotecha, R. R., Trifiletti, D. M., McClelland, S., Kendra, K. L., Williams, N. O., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10092211 · Cited by 7
“Understanding these key signaling pathways has led to the development of novel targeted treatments such as tyrosine kinase inhibitors (TKIs) and immune-related therapy that have demonstrated intracranial efficacy, especially in patients with asymptomatic brain metastases [26].”
BackgroundAdvanced Breast Cancer: AGO Recommendations 2022 – Focus on ABC6 Consensus
Untch, M., Fasching, P. A., Haidinger, R., Harbeck, N., Jackisch, C., Lüftner, D., Müller, V., Schumacher-Wulf, E., Würstlein, R., & Thomssen, C. (2022) · Geburtshilfe und Frauenheilkunde · doi:10.1055/a-1904-6100 · Cited by 7
“The German experts comment that, in contrast to the HER2-CLIMB study [19], only patients with stable and treatable brain metastases were included in the KAMILLA study.”
InfluentialSelf-citationPyrotinib combining with radiotherapy on breast cancer with brain metastasis
Ma, X., Li, Y., Zhao, Z., Li, L., Gao, C., Liu, D., Li, B., & Zhao, B. (2022) · Experimental Biology and Medicine · doi:10.1177/15353702221142605 · Cited by 7
Tyrosine kinase inhibitor toxicities: A society of gynecologic oncology review and recommendations
Rimel, B. J., Crane, E. K., Hou, J. Y., Nakayama, J. M., MacDonald, J. K., Lutz, K., Makker, V., & O'Cearbhaill, R. E. (2023) · Gynecologic Oncology · doi:10.1016/j.ygyno.2023.05.007 · Cited by 7
Karakaya, S., Karadağ, İ., Ateş, Ö., Öksüzoğlu, B. Ç., & Demırcı, U. (2021) · Journal of College of Physicians And Surgeons Pakistan · doi:10.29271/jcpsp.2021.02.166 · Cited by 7
DESTINY-Breast01 Trial: trastuzumab deruxtecan in previously treated HER2 positive breast cancer
Jackson, E. B., Simmons, C. E., & Gelmon, K. A. (2021) · Translational Breast Cancer Research · doi:10.21037/tbcr-21-20 · Cited by 7
Self-citationBreast Cancer Brain Metastasis: Bridging Biological Mechanisms to Therapeutic Innovations
Feng, J. Q., Tao, Y., Li, F., & Liu, S. (2025) · MedComm – Oncology · doi:10.1002/mog2.70043 · Cited by 6
CDK4/6 Inhibitors in HER2-positive Metastatic Breast Cancer
Bischoff, H., & Petit, T. (2026) · Clinical Breast Cancer · doi:10.1016/j.clbc.2026.01.003 · Cited by 6
Wen, X., Wang, W., Song, J., Chen, M., Xue, W., Lin, D., Li, X., Zhang, W., Shen, J., & Zeng, D. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2026.105179 · Cited by 8
Murthy, R. K., O'Brien, B. J., Berry, D. A., Raghavendra, A. S., Monroe, M. G., Johnson, J., White, J., Schwartz-Gomez, J., Topletz‐Erickson, A. R., Lobbous, M., et al. (2026) · Nature Cancer · doi:10.1038/s43018-026-01120-7 · Cited by 10
Self-citationTrifanescu, O. G., Mitrea, D., Gales, L. N., Ciornei, A., Păun, M.-A., Butnariu, I., Trifanescu, R. A., Motaș, N., Toma, R.-V., Bîlteanu, L., et al. (2023) · Cancers · doi:10.3390/cancers15092508 · Cited by 7
“The HER2CLIMB trial demonstrated that adding a highly selective HER2 TKI like Tucatinib can improve the CNS-PFS of patients with brain metastases from 4.2 months to 9.9 months and increase the OS from 12 to 18.1 months.”
BackgroundInfluentialSilvestri, V. L., Tran, A. D., Chung, M. A., Chung, N., Gril, B., Robinson, C. M., Difilippantonio, S., Wei, D., Kruhlak, M. J., Peer, C. J., et al. (2024) · Neuro-Oncology · doi:10.1093/neuonc/noae025 · Cited by 7
Garrone, O., Ruatta, F., Rea, C. G., Denaro, N., Ghidini, M., Cauchi, C., Bareggi, C., Galassi, B., Merlano, M. C., & Rosenfeld, R. (2024) · Cancers · doi:10.3390/cancers16244164 · Cited by 7
“Importantly, intracranial PFS and OS reached 9.9 and 18.1 months, respectively, whereas the ORR was 47.3% among patients with measurable BMs [18].”
InfluentialHuang, T., Wu, D., Jiang, L., Wu, Z., Zhao, Y., Tang, F., Mou, Z., Pan, C., Liu, Y., Tong, A., et al. (2025) · International Journal of Cancer · doi:10.1002/ijc.35421 · Cited by 6
“88,89 For example, stereotactic radiosurgery (SRS) remains a cornerstone for local control, 90 while targeted agents such as trastuzumab-capecitabine and tucatinib have significantly improved intracranial response rates in HER2-positive BrM. 91 Recent clinical trials have also demonstrated the efficacy of antibody-dru…”
InfluentialChen, W., Qin, Y., Qiao, L., Liu, X., Gao, C., Li, T., Luo, Y., Li, D., Yan, H., Han, L., et al. (2025) · Science Advances · doi:10.1126/sciadv.adt3075 · Cited by 7
Wang, C., Fan, P., Zhou, Y., Ma, M., Zhong, H., Liu, L., Chen, Q., & Xu, K. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06660-7 · Cited by 8
“…exploratory clinical trials (e.g. tucatinib plus trastuzumab and capecitabine for HER2-positive BCBrM patients in the phase 2 HER2CLIMB trial [40], radiotherapy plus pyrotinib and capecitabine for HER2-positive BCBrM patients in a Chinese phase 2 trial [41], trastuzumab der-uxtecan for…”
Huebner, H., Kurbacher, C. M., Kuesters, G. M., Hartkopf, A. D., Lux, M. P., Huober, J., Volz, B., Taran, F., Overkamp, F., Tesch, H., et al. (2020) · BMC Cancer · doi:10.1186/s12885-020-07546-1 · Cited by 6
Self-citationChen, F., Chen, N., Lv, Z., Li, L., & Cui, J. (2021) · Journal of Cancer · doi:10.7150/jca.51845 · Cited by 6
“Furthermore, several new drugs such as tucatinib [57-61], margetuximab (MGAH22) [62-64] and antibody-conjugated drug trastuzumab deruxtecan (DS-8201) [65, 66] all have shown encouraging efficacy and safety in patients who progressed after receiving multiple anti-HER2 treatments.”
BackgroundAlhalabi, O., Soomro, Z., Sun, R., Hasanov, E., Albittar, A. A., Tripathy, D., Valero, V., & Ibrahim, N. K. (2021) · npj Breast Cancer · doi:10.1038/s41523-021-00235-7 · Cited by 6
Metadata
- Authors
- Murthy, R. K., Loi, S., Okines, A., Paplomata, E., Hamilton, E., Hurvitz, S. A., Lin, N. U., Borges, V., Abramson, V., Anders, C., Bedard, P. L., Oliveira, M., Jakobsen, E., Bachelot, T., Shachar, S. S., Müller, V., Braga, S., Duhoux, F. P., Greil, R., Cameron, D., Carey, L. A., Curigliano, G., Gelmon, K., Hortobagyi, G., Krop, I., Loibl, S., Pegram, M., Slamon, D., Palanca-Wessels, M. C., Walker, L., Feng, W., & Winer, E. P.
- Affiliations
- Royal Marsden NHS Foundation Trust (GB)
- From M.D. Anderson Cancer Center, Houston (R.K.M., G.H.); Peter MacCallum Cancer Centre, Melbourne, VIC, Australia (S. Loi); the Royal Marsden NHS Foundation Trust, London (A.O.), and Edinburgh Cancer Research Centre, Edinburgh (D.C.) — both in the United Kingdom; Winship Cancer Institute, Atlanta (E.P.); Sarah Cannon Research Institute/Tennessee Oncology–Nashville (E.H.) and Vanderbilt University Medical Center (V.A.), Nashville; University of California, Los Angeles, Medical Center–Jonsson...
- BC Cancer Agency (CA)
- ORCID
- Murthy, Rashmi K.
- Loi, Sherene
- Okines, Alicia
- Hamilton, Erika
- Hurvitz, Sara A.
- Borges, Virginia
- Abramson, Vandana
- Anders, Carey
- Bedard, Philippe L.
- Oliveira, Mafalda
- Jakobsen, Erik
- Bachelot, Thomas
- Shachar, Shlomit S.
- Müller, Volkmar
- Braga, Sofia
- Duhoux, Francois P.
- Greil, Richard
- Cameron, David
- Curigliano, Giuseppe
- Gelmon, Karen
- Krop, Ian
- Loibl, Sibylle
- Pegram, Mark
- Slamon, Dennis
- Palanca-Wessels, M. Corinna
- Feng, Wentao
- Winer, Eric P.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-02-13
- Volume
- 382
- Issue
- 7
- Pages
- 597-609
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2995808512
- Cited by
- 1,326
- References
- 29
- Citations by year
- 2026: 118 · 2025: 158 · 2024: 203 · 2023: 197 · 2022: 252 · 2021: 244 · 2020: 152
- FWCI
- 67.71
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- Edinburgh Research Explorer (University of Edinburgh) (submittedVersion, other-oa)
- HAL (submittedVersion)
- Digital Access to Libraries (submittedVersion, other-oa)
- University of Southern Denmark Research Portal (University of Southern Denmark) (submittedVersion, other-oa)
- UNC Libraries
- Funders
- Seattle Genetics
- Topics
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Health Sciences › Medicine › Oncology › Gastric Cancer Management and Outcomes
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- tucatinib, HER2-positive metastatic breast cancer, trastuzumab, capecitabine, HER2 tyrosine kinase inhibitor, brain metastases, progression-free survival, overall survival, pertuzumab, trastuzumab emtansine, HER2-targeted therapy, diarrhea, hand-foot syndrome
- MeSH terms
- Trastuzumab, Capecitabine, Progression-Free Survival, Aged, Antineoplastic Combined Chemotherapy Protocols, Brain Neoplasms, Breast Neoplasms, Diarrhea, Double-Blind Method, Female, Humans, Middle Aged, Oxazoles, Protein-Tyrosine Kinases, Pyridines, Quinazolines, Receptor, ErbB-2, Erb-b2 Receptor Tyrosine Kinases, Kaplan-Meier Estimate, Consolidation Chemotherapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.